LiquidCell Dx, a next-generation cancer diagnostics company based in San Carlos, California, announced today the publication of research in Nature supporting the development of its LiquidTME assay. The blood-based test is designed to analyze the tumor microenvironment and forecast therapy response.
The study, published on May 7, 2026, demonstrates that liquid biopsy of the tumor microenvironment can powerfully predict how patients will respond to treatment. The company stated that this approach could enable more personalized cancer care by identifying effective therapies earlier.
LiquidTME is intended to provide a non-invasive alternative to traditional tissue biopsies, potentially reducing patient risk and allowing for repeated sampling over time. The Nature paper details the underlying science and validation of the assay.
